Over the past two decades, research has heavily emphasized basic mechanisms that
irreversibly damage brain cells after stroke. Much attention has focused on what makes …

While the mainstay of acute stroke treatment includes revascularization via recombinant
tissue plasminogen activator or mechanical thrombectomy, only a minority of stroke patients …

Ischemic stroke (IS) is one of the most common causes of disability and death. Thrombolysis
and neuroprotection are two current major therapeutic strategies to overcome ischemic and …

Ischemic stroke continues to be one of the most challenging diseases in translational
neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for …

The past decade has resulted in a rapid increase in knowledge of mechanisms underlying
brain injury induced by intracerebral haemorrhage (ICH). Animal studies have suggested …

Deleterious processes of extracellular proteolysis may contribute to the progression of tissue
damage after acute brain injury. We recently showed that matrix metalloproteinase-9 (MMP …

The blood–brain barrier (BBB) is formed primarily to protect the brain microenvironment from
the influx of plasma components, which may disturb neuronal functions. The BBB is a …

Background and Purpose—Perihematomal edema (PHE) can worsen outcomes after
intracerebral hemorrhage (ICH). Reports suggest that blood degradation products lead to …

Minocycline, a semisynthetic tetracycline derivative, protects brain against global and focal
ischemia in rodents. We examined whether minocycline reduces excitotoxicity in primary …

Drug delivery research pursues many types of carriers including proteins and other
macromolecules, natural and synthetic polymeric structures, nanocarriers of diverse …